The FDA has approved Teva’s abbreviated new drug application for oxcarbazepine tablets at 150mg, 300mg and 600mg milligrams. The drug is used to help control certain kinds of seizures and works by decreasing abnormal excitement in the brain.
Shipment of the product will begin in the near future. Teva is currently involved in patent litigation concerning this product in the US District Court for the district of New Jersey. A trial date has not been set.